1. Home
  2. VSECU vs AGIO Comparison

VSECU vs AGIO Comparison

Compare VSECU & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VSE Corporation Tangible Equity Units

VSECU

VSE Corporation Tangible Equity Units

N/A

Current Price

$48.12

Market Cap

1.5B

Sector

N/A

ML Signal

N/A

Logo Agios Pharmaceuticals Inc.

AGIO

Agios Pharmaceuticals Inc.

HOLD

Current Price

$29.60

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VSECU
AGIO
Founded
N/A
2007
Country
United States
United States
Employees
1400
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
VSECU
AGIO
Price
$48.12
$29.60
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
$37.63
AVG Volume (30 Days)
13.5K
623.7K
Earning Date
N/A
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$43,011,000.00
Revenue This Year
N/A
$71.05
Revenue Next Year
N/A
$163.65
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$46.90
$22.24
52 Week High
$58.93
$46.00

Technical Indicators

Market Signals
Indicator
VSECU
AGIO
Relative Strength Index (RSI) 40.52 59.42
Support Level N/A $26.48
Resistance Level $57.23 $30.90
Average True Range (ATR) 0.95 0.97
MACD -0.70 0.06
Stochastic Oscillator 21.97 82.43

Price Performance

Historical Comparison
VSECU
AGIO

About VSECU VSE Corporation Tangible Equity Units

VSE Corp is a diversified aftermarket products and services company serving commercial and government markets. The Company's operations include aircraft and airframe parts supply and distribution, and MRO services of aircraft components and engine accessories. The Company operates as a single reportable segment: Aviation, which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

Share on Social Networks: